Search

Displaying results 7781 - 7790 of 10000 in total
  1. Drug

    Linafexor

    go.drugbank.com/drugs/DB18031
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    BHT-3034

    go.drugbank.com/drugs/DB18045
    Experimental

    BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]

  3. Drug

    Lisaftoclax

    go.drugbank.com/drugs/DB18054
    Investigational

    Lisaftoclax is a novel, orally active, selective and potent BCL-2 inhibitor

  4. Drug

    DTx-1252

    go.drugbank.com/drugs/DB18086
    Experimental

    DTx-1252 is a siRNA therapeutic under investigation for the treatment of Charcot-Marie-Tooth Disease type 1A (CMTD1A).[L48096]

  5. Drug

    PLG-0206

    go.drugbank.com/drugs/DB18116
    Investigational

    PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.[L48106]

  6. Drug

    PBKR03

    go.drugbank.com/drugs/DB18138
    Investigational

    PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.

  7. Drug

    TN-401

    go.drugbank.com/drugs/DB18140
    Investigational

    TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.

    Synonyms: A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene
  8. Drug

    Gunagratinib

    go.drugbank.com/drugs/DB18191
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Efocipegtrutide

    go.drugbank.com/drugs/DB18194
    Investigational

    Efocipegtrutide is a long-acting, monomeric peptide triple agonist.

  10. Drug

    XMT-2056

    go.drugbank.com/drugs/DB18230
    Investigational

    XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.